[8-K] Inhibrx Biosciences, Inc. Reports Material Event

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. furnished a press release announcing its financial results for the three and six months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and an interactive XBRL cover page is included as Exhibit 104.

The company states the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, so it is subject to different legal treatment than filed disclosures. The report confirms Inhibrx's Nasdaq listing under the ticker INBX and indicates the registrant is an emerging growth company.

Positive

• Press release announcing quarterly results furnished as Exhibit 99.1
• Interactive XBRL cover page (Exhibit 104) included to support data accessibility
• Company confirms Nasdaq listing under ticker INBX and emerging growth company status

Negative

• The 8-K does not include the financial figures or tables within the filing text; investors must review Exhibit 99.1 for details
• Information is "furnished" and expressly not deemed "filed" under Section 18, limiting legal remedies tied to filed disclosures

Insights

Financial Analyst

TL;DR: Inhibrx furnished Q2 2025 results via a press release; the 8-K does not include the financial figures themselves.

The 8-K notifies investors that Inhibrx has issued a press release covering results for the three- and six-month periods ended June 30, 2025, and furnishes that release as Exhibit 99.1. The 8-K itself contains no financial tables or metrics, so material details must be obtained from the attached press release. Because the disclosure is "furnished" rather than "filed," it is not subject to Section 18 liability, which limits the legal status of the information in the 8-K. Impact is neutral pending review of the press release.

Corporate Governance Expert

TL;DR: The company furnished a press release and included Interactive XBRL; the disclosure is expressly not "filed," which affects legal recourse.

This Current Report serves to furnish a corporate communication (press release) under Item 2.02 and to provide the corresponding exhibits. The filing reiterates the distinction between "furnished" and "filed" materials, which means the press release is provided for investor information but carries different legal implications than a filed submission. The inclusion of an Interactive XBRL cover page improves accessibility of tagged data, but the 8-K itself does not present financial figures for analysis.

FALSE000200791900020079192025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

INHIBRX BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)  

Delaware

001-42031

99-0613523

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

11025 N. Torrey Pines Road, Suite 140

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 795-4220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			INBX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 2.02    Results of Operations and Financial Condition

On August 13, 2025, Inhibrx Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release issued by Inhibrx Biosciences, Inc. on August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2025
			INHIBRX BIOSCIENCES, INC.
			By:			/s/ Kelly Deck
			Name:			Kelly Deck
			Title:			Chief Financial Officer

FAQ

When did Inhibrx (INBX) announce its Q2 2025 results?

The company issued a press release on August 13, 2025 announcing results for the three and six months ended June 30, 2025.

Is the press release in the 8-K considered "filed" with the SEC?

No. The 8-K states the information and Exhibit 99.1 are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can investors find the press release referenced in the 8-K?

The press release is furnished as Exhibit 99.1 to the Current Report; an Interactive XBRL cover page is included as Exhibit 104.

What is Inhibrx's trading symbol and exchange?

Inhibrx trades as INBX on the Nasdaq Global Market.

Who signed the Current Report on behalf of Inhibrx?

The report is signed by Kelly Deck, Chief Financial Officer of Inhibrx Biosciences, Inc.